178 related articles for article (PubMed ID: 38498120)
1. The protective effects of Ninjin'yoeito against liver steatosis/fibrosis in a non-alcoholic steatohepatitis model mouse.
Takano K; Kaneda M; Aoki Y; Fujita N; Chiba S; Michihara S; Han LK; Takahashi R
J Nat Med; 2024 Jun; 78(3):514-524. PubMed ID: 38498120
[TBL] [Abstract][Full Text] [Related]
2. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis.
Matsumoto M; Hada N; Sakamaki Y; Uno A; Shiga T; Tanaka C; Ito T; Katsume A; Sudoh M
Int J Exp Pathol; 2013 Apr; 94(2):93-103. PubMed ID: 23305254
[TBL] [Abstract][Full Text] [Related]
3. Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice.
Susutlertpanya W; Wakuda H; Otani N; Kuramoto T; Li L; Kuranari M; Sekiguchi A; Kudo H; Uchida T; Imai H; Uemura N
Life Sci; 2019 Jul; 228():251-257. PubMed ID: 31078545
[TBL] [Abstract][Full Text] [Related]
4. Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH).
Hartimath SV; Boominathan R; Soh V; Cheng P; Deng X; Chong YC; Yong FF; Tan PW; Han W; Robins EG; Goggi JL
Contrast Media Mol Imaging; 2019; 2019():6298128. PubMed ID: 31866798
[TBL] [Abstract][Full Text] [Related]
5. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
[TBL] [Abstract][Full Text] [Related]
6. Vitronectin deficiency attenuates hepatic fibrosis in a non-alcoholic steatohepatitis-induced mouse model.
Hayashida M; Hashimoto K; Ishikawa T; Miyamoto Y
Int J Exp Pathol; 2019 Apr; 100(2):72-82. PubMed ID: 30887659
[TBL] [Abstract][Full Text] [Related]
7. Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor.
Duan X; Meng Q; Wang C; Liu Z; Liu Q; Sun H; Sun P; Yang X; Huo X; Peng J; Liu K
Phytomedicine; 2017 Feb; 25():83-92. PubMed ID: 28190475
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by
Rokugawa T; Konishi H; Ito M; Iimori H; Nagai R; Shimosegawa E; Hatazawa J; Abe K
EJNMMI Res; 2018 May; 8(1):40. PubMed ID: 29855729
[TBL] [Abstract][Full Text] [Related]
9. Reduced Serum Cholesterol and Triglyceride Levels in a Choline-Deficient L-Amino Acid-Defined High-Fat Diet (CDAHFD)-Induced Mouse Model of Non-alcoholic Steatohepatitis (NASH).
Yasuda D; Torii H; Shimizu R; Hiraoka Y; Kume N
Biol Pharm Bull; 2020; 43(4):616-618. PubMed ID: 32238704
[TBL] [Abstract][Full Text] [Related]
10. Myeloid AMPK signaling restricts fibrosis but is not required for metformin improvements during CDAHFD-induced NASH in mice.
Nunes JRC; O'Dwyer C; Ghorbani P; Smith TKT; Chauhan S; Robert-Gostlin V; Girouard MD; Viollet B; Foretz M; Fullerton MD
J Lipid Res; 2024 Jun; 65(6):100564. PubMed ID: 38762124
[TBL] [Abstract][Full Text] [Related]
11. Time-restricted feeding has a limited effect on hepatic lipid accumulation, inflammation and fibrosis in a choline-deficient high-fat diet-induced murine NASH model.
Sato T; Oishi K
PLoS One; 2024; 19(1):e0296950. PubMed ID: 38285666
[TBL] [Abstract][Full Text] [Related]
12. Gender differences in diet-induced steatotic disease in Cyp2b-null mice.
Heintz MM; McRee R; Kumar R; Baldwin WS
PLoS One; 2020; 15(3):e0229896. PubMed ID: 32155178
[TBL] [Abstract][Full Text] [Related]
13. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
[TBL] [Abstract][Full Text] [Related]
14. Periostin antisense oligonucleotide prevents hepatic steatosis and fibrosis in a mouse model of non-alcoholic steatohepatitis.
Kobayashi T; Kanno K; Nguyen PT; Sugiyama A; Kawahara A; Otani Y; Kishikawa N; Ito M; Tazuma S
J Gastroenterol Hepatol; 2020 Dec; 35(12):2140-2150. PubMed ID: 32365405
[TBL] [Abstract][Full Text] [Related]
15. Long-term profile of serological biomarkers, hepatic inflammation, and fibrosis in a mouse model of non-alcoholic fatty liver disease.
Toita R; Kang JH
Toxicol Lett; 2020 Oct; 332():1-6. PubMed ID: 32579995
[TBL] [Abstract][Full Text] [Related]
16. Effects of Caffeine and Chlorogenic Acid on Nonalcoholic Steatohepatitis in Mice Induced by Choline-Deficient, L-Amino Acid-Defined, High-Fat Diet.
Dungubat E; Watabe S; Togashi-Kumagai A; Watanabe M; Kobayashi Y; Harada N; Yamaji R; Fukusato T; Lodon G; Sevjid B; Takahashi Y
Nutrients; 2020 Dec; 12(12):. PubMed ID: 33353230
[TBL] [Abstract][Full Text] [Related]
17. Yellow loosestrife (Lysimachia vulgaris var. davurica) ameliorates liver fibrosis in db/db mice with methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis.
Son YJ; Jung DS; Shin JM; Kim M; Yoo G; Nho CW
BMC Complement Med Ther; 2021 Jan; 21(1):44. PubMed ID: 33494735
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
[TBL] [Abstract][Full Text] [Related]
19. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
[TBL] [Abstract][Full Text] [Related]
20. NASH-inducing Diets in Göttingen Minipigs.
Pedersen HD; Galsgaard ED; Christoffersen BØ; Cirera S; Holst D; Fredholm M; Latta M
J Clin Exp Hepatol; 2020; 10(3):211-221. PubMed ID: 32405177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
